The global retinal disease therapeutics market is likely to expand at an impressive rate driven by recent government participation towards prevention and control of retinal diseases. According to a report published by Fortune Business Insights, titled “Retinal Disease Therapeutics: Global Market Analysis, Insights, and Forecast, 2019-2026,” the market is likely to reach US$ 21,318.0 Mn by the end of 2026. The market was valued at US$ 11,044.2 Mn in 2018 and is likely to witness a CAGR of 8.6% in the forecast period.
Browse Complete Report Details@ https://www.fortunebusinessinsights.com/industry-reports/retinal-disease-therapeutics-market-100311
“F. Hoffmann-La Roche AG’s ‘Lucentis’ is Gaining Increasing Popularity”
The retinal disease therapeutics market is consolidated in nature, with only a handful of market players accounting for maximum share of the market. With consolidation, it is becoming increasingly difficult for newer market entrants to establish a stronghold or derive immediate success. Therefore the global market is boosted by products and concepts introduced by existing companies.
One such instance of this development is the “Lucentis” therapy, put forward by F. Hoffmann-La Roche AG. Lucentis was introduced with an aim of providing therapeutic advice and development of products for patients suffering from chronic disease. In 2017, the Food and Drug Administration (FDA) approved Lucentis for diabetic retinopathy. The diabetic retinopathy is a severe kind of disorder that has accounted for majority of cases of blindness in the US.
Lucentis was an instant hit among healthcare professionals, after it was backed by a series of clinical trials and aprovals from the National Institute of Health (NIH). Excellent clinical effects of Lucentis have led to a subsequent rise in demand for the medicine among patients. The increasing demand has contributed to the growth of the retinal disease therapeutics market and is likely to favor the market in the forthcoming years.
Get Sample PDF Brochure@ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/retinal-disease-therapeutics-market-100311
Top players profiled in Retinal Disease Therapeutics Market based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
• Merck & Co., Inc.
• Novartis AG
• Allergan plc
• F. Hoffmann-La Roche AG
• Regeneron Pharmaceuticals, Inc.
• Santen Pharmaceutical Co., Ltd.
“North America to Emerge Dominant in the Forecast Period”
The increasing government investment towards research and development of retinal disease drugs and diagnostic devices is enabling growth in the retinal diseases therapeutics market in North America. North America has emerged dominant in the retinal disease therapeutics market in recent years. The retinal disease therapeutics market in North America was valued at US$ 4056.5Mn in 2018 and is likely to increase in the coming years.
Improved health infrastructures, increasing patient pool, and favourable health reimbursement policies are some of the factors that are likely to boost the regional market in the forthcoming years. High prevalence of retinal diseases in Asia Pacific is a major reason, why this region is estimated to rise with the highest CAGR in the forecast period.
Order Full Report@ https://www.fortunebusinessinsights.com/checkout-page/100311
Market Segmentation:
By Disease Indication
• Macular Degeneration
• Diabetic Retinopathy
• Diabetic Macular Edema
• Retinal Vein Occlusion
• Others
By Geography
• North America (USA and Canada)
• Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
• Latin America (Brazil, Mexico, Rest of Latin America)
• Middle East & Africa (GCC, South Africa, Rest of Middle East & Africa)
